DBV Technologies (NASDAQ:DBVT) Given Market Outperform Rating at JMP Securities

JMP Securities reissued their market outperform rating on shares of DBV Technologies (NASDAQ:DBVT) in a report released on Friday morning,Benzinga reports. JMP Securities currently has a $10.00 target price on the stock.

Several other equities analysts have also issued reports on DBVT. StockNews.com started coverage on DBV Technologies in a research report on Thursday. They set a “hold” rating for the company. HC Wainwright boosted their price objective on shares of DBV Technologies from $25.00 to $35.00 and gave the company a “buy” rating in a report on Thursday, October 24th.

DBV Technologies Stock Up 29.8 %

DBVT stock opened at $4.97 on Friday. DBV Technologies has a twelve month low of $2.20 and a twelve month high of $9.49. The company has a market cap of $102.23 million, a P/E ratio of -1.10 and a beta of 0.64. The business’s fifty day moving average is $3.32 and its 200-day moving average is $3.83.

About DBV Technologies

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.